Patent Grant
11898162
Embryonic stem (ES) cells can grow indefinitely while maintaining pluripotency and can differentiate into cells of all three germ layers (Evans & Kaufman, Nature 292:154-156 (1981)). Human ES cells will be useful in treating a host of diseases, such as Parkinson's disease, spinal cord injury and diabetes (Thomson et al., Science 282:1145-1147 (1998)). Scientists have sought technical solutions to avoid the current method of generating ES cells from blastocyst cells and to avoid anticipated tissue rejection problems following transplantation into patients. One desirable way to accomplish these solutions would be to generate pluripotent cells directly from somatic cells of a post-natal individual.
Somatic cells can be reprogrammed by transferring their nuclear contents into oocytes (Wilmut et al., Nature 385:810-813(1997)) or by fusion with ES cells (Cowan et al., Science 309:1369-1373 (2005)), indicating that unfertilized eggs and ES cells contain factors that confer totipotency or pluripotency in somatic cells.
Likewise, Yu et al. showed that cells derived by in vitro differentiation from an H1 Oct4 knock-in ES cells did not express EGFP, but that EGFP expression was restored upon cell-cell fusion with human ES cells. Yu et al., Stem Cells 24:168-176 (2006), incorporated herein by reference as if set forth in its entirety). Therefore, Yu et al. demonstrated that differentiated cells can become pluripotent via cell-cell fusion with human ES cells. Regardless of the differentiated cell type, upon fusion with undifferentiated human ES cells, ES cell specific antigens and marker genes were expressed and differentiation-specific antigens were no longer detectable in the fused hybrid cells. Advantageously, EGFP expression was re-established in the hybrid cells, providing a convenient marker for re-establishment of pluripotent stem cell status. When the hybrid cells formed embryoid bodies (EBs), genes characteristic of all three germ layers and extra-embryonic tissues were up-regulated, indicating that the hybrid cells had a potential to differentiate into multiple lineages.
Although the transcriptional determination of pluripotency is not fully understood, several transcription factors, including Oct 3/4 (Nichols et al., Cell 95:379-391(1998)), Sox2 (Avilion et al., Genes Dev. 17:126-140 (2003)) and Nanog (Chambers et al., Cell 113:643-655(2003)) are involved in maintaining ES cell pluripotency; however, none is sufficient alone to specify ES cell identity.
Chambers & Smith (EP 1 698 639 A2, (2002)) maintained pluripotent murine cells without a feeder layer or feeder cell extract and without a gp130 cytokine by introducing vectors that encode or activate differentiation-suppressing factors, but did not convert differentiated cells into a pluripotent state.
More recently, Takahashi & Yamanaka introduced four factors (i.e., Oct3/4, Sox2, c-Myc and Klf4) into mouse ES cells and mouse adult fibroblasts cultured under conditions suitable for mouse ES cell culture to obtain induced pluripotent stem (iPS) cells that exhibited mouse ES cell morphology and growth properties and expressed mouse ES cell marker genes (Takahashi & Yamanaka, Cell 126:663-676 (2006)). Notably, exogenous Oct-4 introduced into the mouse fibroblasts resulted in only marginal Oct-4 expression. Subcutaneous transplantation of iPS cells into nude mice resulted in tumors containing a variety of tissues from all three germ layers. Following injection into blastocysts, iPS cells contributed to mouse embryonic development. However, c-Myc, which was necessary for pluripotent induction, is an oncogene. Likewise, Klf4 is an oncogene. These data demonstrate that pluripotent cells can be directly generated from mouse fibroblast cultures by adding only a few defined factors using a retroviral transduction. However, as described infra, the set of factors used to produce iPS cells from differentiated mouse cells was insufficient to reprogram human somatic cells to pluripotency using lentiviral vectors without introducing additional changes to the cells.
One could hypothesize that factors that can reprogram human somatic cells differ from those factors that can reprogram somatic cells from model organisms (including mice) because ES cells from mice and humans require distinct sets of factors to remain undifferentiated, illustrating the significance of species-specific differences, even among mammals. For example, the leukemia inhibitory factor (LIF)/Stat3 pathway, a key to mouse ES cell proliferation, does not support human ES cell proliferation and appears inactive in conditions that support human ES cells (Daheron L, et al., Stem Cells 22:770-778 (2004); Humphrey R, et al., Stem Cells 22:522-530 (2004); and Matsuda T, et al., EMBO J. 18:4261-4269 (1999)).
Similarly, while bone morphogenetic proteins (BMPs) together with LIF support mouse ES cell self-renewal at clonal densities in serum-free medium (Ying Q, et al., Cell 115:281-292 (2003)), they cause rapid human ES cell differentiation in conditions that would otherwise support self-renewal, such as culture on fibroblasts or in fibroblast-conditioned medium (Xu R, et al., Nat. Biotechnol. 20:1261-1264 (2002)). Indeed, inhibition of BMP signaling in human ES cells is beneficial (Xu R, et al., Nat. Methods 2:185-190 (2005)).
Still further, fibroblast growth factor (FGF) signaling is important to self-renewal of human ES cells, but apparently not for mice (Xu et al., (2005), supra; and Xu C, et al., Stem Cells 23:315-323 (2005)).
Accordingly, the art still seeks a set of potency-determining factors suited at least for use in methods for reprogramming primate (including human and non-human) somatic cells to yield pluripotent cells. Such cells, obtained without relying upon embryonic tissues, would be suited for use in applications already contemplated for existing, pluripotent, primate ES cells.
The present invention is broadly summarized as relating to methods for reprogramming differentiated, somatic, primate cells into pluripotent cells, and more specifically into iPS cells. As used herein, “iPS cells” refer to cells that are substantially genetically identical to their respective differentiated somatic cell of origin and display characteristics similar to higher potency cells, such as ES cells, as described herein. The cells can be obtained from various differentiated (i.e., non-pluripotent and multipotent) somatic cells.
iPS cells exhibit morphological (i.e., round shape, large nucleoli and scant cytoplasm) and growth properties (i.e., doubling time; ES cells have a doubling time of about seventeen to eighteen hours) akin to ES cells. In addition, iPS cells express pluripotent cell-specific markers (e.g., Oct-4, SSEA-3, SSEA-4, Tra-1-60, Tra-1-81, but not SSEA-1). iPS cells, however, are not immediately derived from embryos and can transiently or stably express one or more copies of selected potency-determining factors at least until they become pluripotent. As used herein, “not immediately derived from embryos” means that the starting cell type for producing iPS cells is a non-pluripotent cell, such as a multipotent cell or terminally differentiated cell, such as somatic cells obtained from a post-natal individual.
In the methods described herein, at least two potency-determining factors can be introduced into, and expressed in, differentiated somatic cells, whereupon the somatic cells convert in culture to cells having properties characteristic of pluripotent cells, such as human ES cells (i.e., express at least Oct-4, SSEA-3, SSEA-4, TRA-1-60 or TRA-1-81, but not SSEA-1, and appear as compact colonies having a high nucleus to cytoplasm ratio and prominent nucleolus), that can differentiate into cells characteristic of all three germ layers, and that contain the genetic complement of the somatic cells of a post-natal individual. Apart from genetic material introduced to encode the potency-determining factors, the reprogrammed (i.e., converted) cells are substantially genetically identical to the somatic cells from which they were derived.
As used herein, a “potency-determining factor” refers to a factor, such as a gene or other nucleic acid, or a functional fragment thereof, as well as an encoded factor or functional fragment thereof, used to increase the potency of a somatic cell, so that it becomes pluripotent. The potency-determining factors optionally can be present only transiently in the reprogrammed cells or can be maintained in a transcriptionally active or inactive state in the genome of the reprogrammed cells. Likewise, the potency-determining factors can be present in more than one copy in the reprogrammed cells, where the potency-determining factor can be integrated in the cell's genome, can be extra-chromosomal or both. The potency-determining factors can include, but are not limited to, Stella (SEQ ID NO:1); POU5F1 (Oct-4; SEQ ID NO:2), Sox2 (SEQ ID NO:3), FoxD3, UTF1, Rex1, ZNF206, Sox15, Myb12, Lin28 (SEQ ID NO:4), Nanog (SEQ ID NO:5), DPPA2, ESG1, Otx2 and subsets thereof. In some embodiments, as few as two potency-determining factors, e.g., Oct-4 and Sox2, can be sufficient. Efficiency in obtaining reprogrammed cells, however, can be improved by including additional potency-determining factor, such as Lin28, Nanog or both.
In a first aspect, the invention relates to a replenishable, enriched population of pluripotent cells obtained from a post-natal individual, especially from a living individual, but optionally from a deceased individual. Cells in the enriched cell population express at least one cell-type-specific marker, including, but not limited to, Oct-4, SSEA3, SSEA4, Tra-1-60, Tra-1-81 or combinations thereof and have other hallmarks of pluripotent cells, such as ES cells. In addition, the pluripotent cells may express alkaline phosphatase (ALP). Furthermore, the pluripotent cells may have a genome substantially genetically identical to that of a pre-existing, differentiated cell from the individual. Likewise, the pluripotent cells may have a genome that encodes at least one of the potency-determining factors, which may be transcriptionally active or inactive after reprogramming. Additionally, the potency-determining factors may be in a form of a reprogramming sequence in which a polynucleotide encoding the potency-determining factor is operably linked to a heterologous promoter. As used herein, “heterologous promoter” means a promoter that is operably linked to a polynucleotide for which the promoter does not normally initiate transcription.
In a second aspect, the invention relates to methods and compositions for identifying potency-determining factors required to reprogram somatic cells into pluripotent cells.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although suitable methods and materials for the practice or testing of the present invention are described below, other methods and materials similar or equivalent to those described herein, which are well known in the art, can also be used.
Other objects, advantages and features of the present invention will become apparent from the following specification taken in conjunction with the accompanying drawings.
The inventors hypothesized that potency-determining factors present in primate ES cells play an important role in maintaining pluripotency and that differentiated somatic cells could be reprogrammed to a state of pluripotency through expression of potency-determining factors.
Cell types pass through various levels of potency during differentiation, such as totipotency, pluripotency and multipotency. Of particular interest herein are pluripotent cells. As used herein, “pluripotent cells” refer to a population of cells that can differentiate into all three germ layers (e.g., endoderm, mesoderm and ectoderm). Pluripotent cells express a variety of pluripotent cell-specific markers, have a cell morphology characteristic of undifferentiated cells (i.e., compact colony, high nucleus to cytoplasm ratio and prominent nucleolus) and form teratomas when introduced into an immunocompromised animal, such as a SCID mouse. The teratomas typically contain cells or tissues characteristic of all three germ layers. One of ordinary skill in the art can assess these characteristics by using techniques commonly used in the art. See, e.g., Thomson et al., supra. Pluripotent cells are capable of both proliferation in cell culture and differentiation towards a variety of lineage-restricted cell populations that exhibit multipotent properties. Multipotent somatic cells are more differentiated relative to pluripotent cells, but are not terminally differentiated. Pluripotent cells therefore have a higher potency than multipotent cells. As used herein, “reprogrammed pluripotent primate stem cells” (and similar references) refer to the pluripotent products of somatic cell reprogramming methods. Such cells are suitable for use in research and therapeutic applications currently envisioned for human ES cells.
The present invention broadly relates to novel methods for reprogramming differentiated somatic cells into higher-potency cells, such as pluripotent cells, by administering at least two potency-determining factors into somatic cells to achieve a higher level of potency in the reprogrammed cells than in the somatic cells. Advantageously, the present invention allows the generation of pluripotent cells, such as iPS cells, from somatic cells without requiring an addition of cell surface receptors for introducing the potency-determining factors to the somatic cells. As used herein, “reprogramming” refers to a genetic process whereby differentiated somatic cells are converted into de-differentiated, pluripotent cells, and thus have a greater pluripotency potential than the cells from which they were derived. That is, the reprogrammed cells express at least one of the following pluripotent cell-specific markers: SSEA-3, SSEA-4, TRA-1-60 or TRA 1-81. Preferably, the reprogrammed cells express all these markers.
Potency-determining factors that can reprogram somatic cells include, but are not limited to, factors such as Oct-4, Sox2, FoxD3, UTF1, Stella, Rex1, ZNF206, Sox15, Myb12, Lin28, Nanog, DPPA2, ESG1, Otx2 or combinations thereof. In the examples, a set with as few as two of the fourteen factors was sufficient to reprogram the tested cells; this set included Oct-4 and Sox2. Addition of other potency-determining factors to Oct-4 and Sox2, however, increased the efficiency with which reprogrammed cells were obtained. c-Myc and Klf4, however, are not essential as potency-determining factors. Preferably, the potency-determining factor may be a transcription factor.
Suitable somatic cells can be any somatic cell, although higher reprogramming frequencies are observed when the starting somatic cells have a doubling time about twenty-four hours. Somatic cells useful in the invention are non-embryonic cells obtained from a fetal, newborn, juvenile or adult primate, including a human. Examples of somatic cells that can be used with the methods described herein include, but are not limited to, bone marrow cells, epithelial cells, fibroblast cells, hematopoietic cells, hepatic cells, intestinal cells, mesenchymal cells, myeloid precursor cells and spleen cells. Another type of somatic cell is a CD29+ CD44+ CD166+ CD105+ CD73+ and CD31− mesenchymal cell that attaches to a substrate. Alternatively, the somatic cells can be cells that can themselves proliferate and differentiate into other types of cells, including blood stem cells, muscle/bone stem cells, brain stem cells and liver stem cells. Multipotent hematopoietic cells, suitably myeloid precursor or mesenchymal cells, are specifically contemplated as suited for use in the methods of the invention.
Likewise, suitable somatic cells are receptive, or can be made receptive using methods generally known in the scientific literature, to uptake of potency-determining factors including genetic material encoding the factors. Uptake-enhancing methods can vary depending on the cell type and expression system. Exemplary conditions used to prepare receptive somatic cells having suitable transduction efficiency are known in the art and are described in the examples below. One method for making cells receptive to potency-determining factors is described below in connection with the electroporation methods.
A potency-determining factor may be introduced as a reprogramming sequence in which a polynucleotide sequence encoding the potency-determining factor is operably linked to a heterologous promoter, which may become inactive after somatic cells are reprogrammed. The heterologous promoter is any promoter sequence that can drive expression of a polynucleotide sequence encoding the potency-determining factor in the somatic cell, such as, e.g., an Oct4 promoter.
The relative ratio of potency-determining factors may be adjusted to increase reprogramming efficiency. For example, linking Oct-4 and Sox2 in a 1:1 ratio on a single vector increased reprogramming efficiency in cells by a factor of four (
Pluripotent cells can be cultured in any medium used to support growth of pluripotent cells. Typical culture medium includes, but is not limited to, a defined medium, such as TeSR™ (StemCell Technologies, Inc.; Vancouver, Canada), mTeSR™ (StemCell Technologies, Inc.) and StemLine® serum-free medium (Sigma; St. Louis, MO), as well as conditioned medium, such as mouse embryonic fibroblast (MEF)-conditioned medium. As used herein, a “defined medium” refers to a biochemically defined formulation comprised solely of biochemically-defined constituents. A defined medium may also include solely constituents having known chemical compositions. A defined medium may further include constituents derived from known sources. As used herein, “conditioned medium” refers to a growth medium that is further supplemented with soluble factors from cells cultured in the medium. Alternatively, cells can be maintained on MEFs in culture medium.
The inventors used a serial analysis of gene expression (SAGE) library to obtain transcriptome profiles of genes abundant in ES cells. Specifically, a SAGE library was used to identify potency-determining factors that regulate pluripotency and self-renewal in ES cells. SAGE libraries are well-known to one of ordinary skill in the art and are publicly available or can be specifically constructed by companies, such as Agencourt Bioscience Corp. (Beverly, MA).
In another aspect, the invention provides an enriched population of pluripotent cells substantially genetically identical to cells of a post-natal individual. The cells can be obtained by reprogramming somatic cells isolated from the post-natal individual. In some embodiments, the cell population is a purified population, representing at least 60%, 70%, 80% and advantageously greater than 95% of the cells in the population, and any and all whole or partial integers therebetween. The reprogrammed cells are euploid, exhibit cell morphology characteristic of pluripotent cells and express pluripotent cell-specific markers, such as, e.g., Oct-4, SSEA-3, SSEA-4, Tra-1-60, Tra-1-81 or combinations thereof, and form teratomas when introduced into an immunocompromised animal.
Yet another aspect provides methods and compositions for identifying and using potency-determining factors sufficient to reprogram somatic cells into pluripotent cells. As noted herein, the reprogrammed pluripotent cells contain the genetic complement of, and are substantially genetically identical to somatic cells obtained from a post-natal individual. Generally, methods for identifying potency-determining factors include the steps of introducing genetic material encoding one or a plurality of putative potency-determining factors into somatic cells receptive to uptake of the genetic material under conditions effective to express the factors encoded on the introduced genetic material at levels sufficient to reprogram the cells to a less differentiated, higher-potency state; and observing a population of pluripotent cells after introduction of the genetic material. The pluripotent cells can be characterized by cell morphology, pluripotent cell-specific markers or both. Advantageously, the pluripotent cells can be identified by expression in the treated cells of a marker provided in the cells so as to be expressed only upon reprogramming of the cells to a pluripotent state. Through this approach, potency-determining factors capable of reprogramming somatic cells into pluripotent cells can be identified, as is described in the examples below.
Genetic material encoding a potency-determining factor can be introduced by transfection or transduction into the somatic cells using a vector, such as an integrating- or non-integrating vector. Of particular interest herein are retroviral vectors. Retroviral vectors, particularly lentiviral vectors, are transduced by packaging the vectors into virions prior to contact with a cell. After introduction, the DNA segment(s) encoding the potency-determining factor(s) can be located extra-chromosomally (e.g., on an episomal plasmid) or stably integrated into cellular chromosome(s).
A viral-based gene transfer and expression vector is a genetic construct that enables efficient and robust delivery of genetic material to most cell types, including non-dividing and hard-to-transfect cells (primary, blood, stem cells) in vitro or in vivo. Viral-based constructs integrated into genomic DNA result in high expression levels. In addition to a DNA segment that encodes a potency-determining factor of interest, the vectors include a transcription promoter and a polyadenylation signal operatively linked, upstream and downstream, respectively, to the DNA segment. The vector can include a single DNA segment encoding a single potency-determining factor or a plurality of potency-determining factor-encoding DNA segments. A plurality of vectors can be introduced into a single somatic cell. The vector can optionally encode a selectable marker to identify cells that have taken up and express the vector. As an example, when the vector confers antibiotic resistance on the cells, antibiotic can be added to the culture medium to identify successful introduction of the vector into the cells. Integrating vectors can be employed, as in the examples, to demonstrate proof of concept. Retroviral (e.g., lentiviral) vectors are integrating vectors; however, non-integrating vectors can also be used. Such vectors can be lost from cells by dilution after reprogramming, as desired. A suitable non-integrating vector is an Epstein-Barr virus (EBV) vector. Ren C, et al., Acta. Biochim. Biophys. Sin. 37:68-73 (2005); and Ren C, et al., Stem Cells 24:1338-1347 (2006), each of which is incorporated herein by reference as if set forth in its entirety.
The vectors described herein can be constructed and engineered using art-recognized techniques to increase their safety for use in therapy and to include suitable expression elements and therapeutic genes. Standard techniques for the construction of expression vectors suitable for use in the present invention are well-known to one of ordinary skill in the art and can be found in such publications such as Sambrook J, et al., “Molecular cloning: a laboratory manual,” (3rd ed. Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 2001), incorporated herein by reference as if set forth in its entirety.
The ability to identify and enrich for pluripotent cells can be facilitated by providing a non-lethal marker in the somatic cells, such as Green Fluorescent Protein (GFP), Enhanced Green Fluorescent Protein (EGFP) or luciferase, under the control of a promoter active only after the somatic cell has converted to a pluripotent state. A selectable marker gene is used to identify the reprogrammed cells expressing the marker through visible cell selection techniques, such as fluorescent cell sorting techniques. Alternatively, the reprogrammed cells can be produced without a selectable marker. In the examples below, a marker was provided in the genome of the somatic cells downstream of the promoter that regulates Oct-4 expression. The endogenous Oct4 promoter is active in undifferentiated, pluripotent ES cells. A drug-selectable population of Oct-4-expressing ES cells did not persist through the culture period necessary for myeloid differentiation. However, because some Oct-4 expression can persist into early stages of differentiation, it is appropriate to enrich the population for pluripotent cells by selecting colonies having characteristic ES cell morphology and by maintaining the cells under ES cell maintenance culture conditions. It is not intended that all cells in the reprogrammed cell culture have the desired level of potency. Given the inefficiencies of cell sorting technology, the variations in levels of gene expression and other biological effects, some cells in the enriched population may not be pluripotent. However, at a practical level, the reprogrammed cell population derived from somatic cells is enriched for pluripotent cells.
The non-lethal marker can be constructed to enable its subsequent removal using any of a variety of art-recognized techniques, such as removal via Cre-mediated, site-specific gene excision. For example, it may become desirable to delete the marker gene after the pluripotent cell population is obtained, to avoid interference by the marker gene product in the experiment or process to be performed with the cells. Targeted deletions can be accomplished by providing structure(s) near the marker gene that permits its ready excision. That is, a Cre/Lox genetic element can be used. The Lox sites can be built into the cells. If it is desired to remove the marker from the pluripotent cells, the Cre agent can be added to the cells. Other similar systems also can be used. Because Cre/Lox excision can introduce undesirable chromosomal rearrangements and can leave residual genetic material after excision, the inventors recognize the desirability of introducing the potency-determining factors into the somatic cells using non-integrating, episomal vectors and obtaining cells from which the episomal vectors are lost (e.g., at a rate of about 5% per generation) by subsequently withdrawing the drug selection used to maintain the vectors during the reprogramming step.
The following examples are provided as further non-limiting illustrations of methods for identifying potency-determining genes or factors for converting somatic cells into pluripotent cells. In some examples, human H1 Oct4 knock-in ES cells were differentiated in stromal cell co-culture to yield cells suited for use as reprogrammable somatic cells. These cells are a model for cells isolated from a post-natal individual for use in a somatic cell reprogramming method.
The methods were repeated with other differentiated cell types. One cell type was human fetal lung fibroblast cells, IMR-90. See, Nichols W, et al., Science 196:60-63 (1977), incorporated herein by reference as if set forth in its entirety. IMR-90 cells are being extensively characterized by the ENCODE Consortium, are readily available from American Type Culture Collection (ATCC; Manassas, VA; Catalog No. CCL-186), and have published DNA fingerprints that allow independent confirmation of the origin of reprogrammed clones. In addition, these cells proliferate robustly in Eagle's Minimal Essential Medium-10% FBS for more than twenty passages before undergoing senescence, but grow slowly in human ES cell culture conditions, a difference that provides a proliferative advantage to reprogrammed clones and aids in their selection by morphological criteria alone. Other differentiated cell types used in the methods were human post-natal foreskin fibroblast cells (ATCC; Catalog No. CRL-2097) and human adult skin cells (ATCC; Catalog No. CRL-2106).
The cells were made receptive for transduction with a viral expression system as described below. The somatic cells were transduced with polynucleotides encoding potency-determining factors thought to be associated with pluripotency, such that the somatic cells were reprogrammed to pluripotent cells. It is not yet determined whether all fourteen potency-determining factors provided in transduction vectors were taken up and expressed in the somatic cells. Having identified a set of fourteen potency-determining factors, and a subset of at least two of the fourteen factors, sufficient to reprogram somatic cells, the inventors provide one of ordinary skill in art the with the ability to identify one or more specific subsets of the potency-determining factors that are also capable of somatic reprogramming, thereby facilitating identification of other subsets of such potency-determining factors. Accordingly, the methods described below facilitate the identification of the potency-determining factors involved in reprogramming somatic cells into pluripotent cells.
It is specifically envisioned that the set of potency-determining factors sufficient to reprogram somatic cells can vary with the cell type of the somatic cells. It is noted that exposure to a set of fourteen potency-determining factors resulted in conversion to a pluripotent status in cultures of the indicated somatic cells. As shown below, one can identify a set of potency-determining factors sufficient to reprogram other cell types by repeating the methods described below using different combinations of potency-determining factors, which may include some or all of the fourteen factors as well as other potency-determining factors. Consequently, one can produce pluripotent cell lines/populations that are substantially genetically identical to a pre-existing, differentiated, somatic cell.
In the following examples, differentiated cells received vectors that encoded various potency-determining factors. Some of the cells contained in their genome a marker gene that encodes EGFP positioned downstream from the regulated Oct4 promoter, which is active only in pluripotent cells. The production of this useful tool is described in Yu et al., supra, which demonstrated that differentiated cells can become pluripotent via cell-cell fusion with human ES cells.
Transgene-expressing lentivirus vector was produced in 293FT cell lines (Invitrogen). 293T is a fast-growing, highly transfectable clonal variant derived from transformed 293 embryonal kidney cells, which contains the large T antigen for high-level expression of the packaging proteins that contribute to higher viral titers. For routine maintenance and expansion, these cells were cultured in 293FT medium (DMEM/10% FBS, 2 mM L-glutamine and 0.1 mM MEM Non-Essential Amino Acids) in the presence of 500 μg/ml geneticin. For packaging, 293FT cells were collected by trypsinization. Following removal of trypsin by centrifugation, these cells were aliquoted into T75 flasks (15×106 cells/flask, and 6 flasks per construct) in 293FT medium without geneticin.
Co-transfection of lentiviral vector and two helper plasmids was carried out with Superfect® transfection reagent (Qiagen) immediately following cell aliquoting (lentiviral vector: MD.G:pCMVdeltaR8.9:Superfect®=5:5:10 μg:40 μl in 400 μl of Iscove's Modified Dulbecco's Medium (IMDM) (1×)/flask incubated at room temperature for 10 minutes). The next day, the culture medium containing the transfection mixture was replaced with fresh 293FT medium supplemented with 1 mM sodium pyruvate (8 ml/flask). Lentivirus-containing supernatant was collected around 48 to 72 hours after transduction (˜48 ml per construct). The 293FT cell debris was removed from the supernatant by centrifugation at 3000 rpm (1750 g) for 15 minutes at 4° C. To concentrate the lentivirus, the supernatant was filtered through 0.4 μM cellulose acetate (CA) membrane (Cornington, 115 ml low-protein binding), and ultracentrifuged in 70 ml sterilized bottles (Beckman, Cat #355622, polycarbonate for 45Ti rotor only) at 33,000 rpm (50,000 g) for 2.5 hours at 4° C. Lentivirus along with any remaining cell debris formed a visible pellet at the bottom of the centrifuge tube. Following supernatant removal, PBS (˜300 μl for each construct) was added to resuspend the pellet by rocking the centrifuge tubes at 4° C. for 8 to 14 hours, or at room temperature for 2 hours. The remaining cell debris was removed by centrifugation at 5000 rpm (2700 g) for 5 minutes, and the resuspended lentivirus was aliquoted and stored at −80° C. The titer obtained generally ranged between 107 to 108 viral particles (vp)/ml after concentration. The sequence for a lentivirus (pSIN4-EF2-Stella-puro; SEQ ID NO:6, with the sequence for Stella from 3604 to 4083) harboring Stella (SEQ ID NO:1) is provided in the Sequence Listing. The same sequence was used for all other potency-determining factors (e.g., SEQ ID NOS: 2-5), except that the sequence for Stella (SEQ ID NO:1) was replaced with the sequence of another potency-determining factor.
To efficiently introduce potency-determining factors into myeloid cells, inventors modified the lentiviral expression system (
To identify genes capable of reprogramming differentiated cells back to a state of pluripotency, efficient transduction of the cells is required. Inventors first tested the lentiviral transduction efficiency immediately after Percoll® purification of a human H1 Oct4 knock-in ES cells (
H1.1 human ES cells (WiCell Research Institute; Madison, WI) were maintained on irradiated mouse embryonic fibroblasts (MEFs) in DMEM/F12 culture medium consisting of 80% Dulbecco's modified Eagle's medium (no pyruvate, high glucose formulation; Invitrogen; Carlsbad, CA) supplemented with 20% KnockOut serum replacer, 1% non-essential amino acids (Gibco), 1 mM L-glutamine, 0.1 mM β-mercaptoethanol (Sigma) and 4 ng/ml basic fibroblast growth factor (bFGF) (all from Invitrogen unless otherwise noted), as previously described (see Amit et al., Dev Biol. 227:271-278 (2000); and Thomson et al., Science 282:1145-1147 (1998), each of which is incorporated herein by reference as if set forth in its entirety). Feeder-free culture on Matrigel® (BD Biosciences; Bedford, MA) with chemically defined TeSR™ medium (StemCell Technologies, Inc.) was carried out as described in Ludwig et al. Ludwig T, et al, Nat. Methods. 3:637-646 (2006); and Ludwig T, et. al., Nat. Biotechnol. 24:185-187 (2006), each of which is incorporated herein by reference as if set forth in its entirety.
The H1 Oct4 knock-in ES cell line was generated from the H1.1 human ES cells according to a method described by Zwaka & Thomson. U.S. Patent Publication No. 2006/0128018 and Zwaka T & Thomson J, Nat. Biotechnol. 21:319-321 (2003), each of which is incorporated herein by reference as if set forth in its entirety. Briefly, a gene targeting vector was constructed by inserting a cassette, an IRES-EGFP, an IRES-NEO and a simian virus polyadenylation sequence (approximately 3.2 kilobases (kb)) into the 3′ untranslated region of the fifth exon of the human Oct-4 (octamer-binding transcription factor 4) gene, also known as POU domain, class 5, transcription factor 1 (POU5F1). This cassette was flanked in the 5′ direction by a 6.3 kb homologous arm and by a 1.6 kb (6.5 kb in the alternative targeting vector) homologous arm in the 3′ region (
For electroporation, cells were harvested with collagenase IV (1 mg/ml, Invitrogen) for 7 minutes at 37° C., washed with medium and re-suspended in 0.5 ml culture medium (1.5-3.0×107 cells). To prepare the cells for electroporation, cells were added to 0.3 ml phosphate-buffered saline (PBS; Invitrogen) containing 40 mg linearized targeting vector DNA. Cells were then exposed to a single 320 V, 200 μF pulse at room temperature using a BioRad Gene Pulser® II (0.4 cm gap cuvette). Cells were incubated for ten minutes at room temperature and were plated at high-density on Matrigel®. G418 selection (50 mg/ml; Invitrogen) was started 48 hours after electroporation. After one week, G418 concentration was doubled. After three weeks, surviving colonies were analyzed individually by PCR using primers specific for the NEO cassette and for the POU5F1 gene just downstream of 3′ homologous region, respectively. PCR-positive clones were re-screened by Southern blot analysis using BamHI digested DNA and a probe outside the targeting construct.
The H1 Oct4 knock-in ES cell line expressed both EGFP and neomycin phosphotransferase (neo) from an endogenous Oct4 promoter/regulatory region using dual internal ribosome-entry sites (IRES) (
H1 Oct4 knock-in ES cells were maintained through co-culture with mouse OP9 bone marrow stromal cells (
For reprogramming, H1 Oct4 knock-in ES cells were differentiated into attached cells (i.e., CD29+CD44+CD166+CD105+CD73+CD31−). Briefly, human H1 Oct4 knock-in ES cells (p76 to 110) were added to the OP9 monolayer (1.5×106/10-cm dish) in 20 ml of DMEM medium supplemented with 10% FBS (HyClone Laboratories) and 100 μM monothioglycerol (MTG; Sigma; St. Louis, MO). The human ES/OP9 cell co-culture was incubated for nine days with changes of half of the medium on days 4, 6 and 8. After incubation, the co-culture was dispersed into individual cells by collagenase IV treatment (1 mg/ml in DMEM medium, Invitrogen) for 20 minutes at 37° C., followed by trypsin treatment (0.05% Trypsin/0.5 mM EDTA, Invitrogen) for 15 minutes at 37° C. Cells were washed twice with medium and re-suspended at 2×106/ml in DMEM medium supplemented with 10% FBS, 100 μM MTG and 100 ng/ml GM-CSF (Leukine; Berlex Laboratories Inc.; Richmond, CA). Cells were further cultured in flasks coated with poly (2-hydroxyethyl methacrylate) (pHEMA; Sigma) for 10 days with changes of half of the medium every 3 days. During adhesion-preventing pHEMA culture, cells that would otherwise be adherent formed floating aggregates, while the cells of interest grew as individual cells in suspension. Large cell aggregates were removed by filtration through 100 μM cell strainers (BD Biosciences), while small aggregates and dead cells were removed by centrifugation through 25% Percoll® (Sigma). The differentiated cells recovered from the cell pellet expressed CD33, MPO, CD11b and CD11c molecules, which are characteristic for bone marrow myeloid cells (
Lentivirus encoding a potency-determining factor (MOI: 3 to 10) was added to the cell culture after addition of polybrene carrier at a final concentration of 6 μg/ml (Sigma). The lentivirus-containing medium was replaced with fresh medium the next day, and cells were cultured further in appropriate medium. Drug selection, if needed, started the third day after transduction. As shown in
On the other hand, cells having high transduction efficiency were prepared as follows. The Percoll®-purified H1 Oct4 knock-in ES cells were allowed to differentiate further to mesenchymal-like cells for an additional seven days in the presence of GM-CSF on Matrigel®, as described above. Many cells attached to the plate during this culture period. The attached cells (referred to herein below as Oct4KICD45+A cells, or simply as CD45+A cells) showed significantly higher transduction efficiency (
Inventors tested the hypothesis that differentiated cells could be reprogrammed to a state of pluripotency by expressing potency-determining factors in Oct4KICD45+A cells (
The Oct4KICD45+A cells were first dissociated to individual cells with trypsin and replated onto Matrigel® at ˜105 cells/well of 6-well plates in TeSR™ medium. Transgene-expressing lentiviral transduction was carried out the next day. Nanog-expressing Oct4KICD45+A cells showed similar morphology to that of EGFP transfected cells (
Cells were analyzed using cell-sorting methods before and after exposing the somatic cells to the factors. Adherent cells were individualized by trypsin treatment (0.05% Trypsin/0.5 mM EDTA, Invitrogen), and fixed in 2% paraformaldehyde for 20 minutes at room temperature. The cells were filtered through a 40-μm mesh, and resuspended in FACS buffer (PBS containing 2% FBS and 0.1% sodium azide). Cells grown in suspension were stained in the FACS buffer supplemented with 1 mM EDTA and 1% normal mouse serum (Sigma). Intracellular myeloperoxidase (MPO) staining was performed using Fix & Perm® reagents (Caltag Laboratories; Burlingame, CA). About 100 μl of cell suspension containing 5×105 cells was used in each labeling. Both primary and secondary antibody incubation (where applied) were carried out at room temperature for 30 minutes. Control samples were stained with isotype-matched control antibodies. After washing, the cells were resuspended in 300-500 μl of the FACS buffer, and analyzed on a FACSCalibur flow cytometer (BDIS; San Jose, CA) using CellQuest™ acquisition and analysis software (BDIS). A total of 20,000 events were acquired. All of the antibodies used in the flow cytometry analysis are listed in Table 1. The final data and graphs were analyzed and prepared using FlowJo software (Tree Star, Inc.; Ashland, OR).
To further evaluate the potency-determining factors involved in reprogramming these cells, inventors explored the transduction of pools of ES cells enriched with various combinations of potency-determining factors. An exemplary pool of potency-determining factors for reprogramming myeloid precursors included the fourteen potency-determining factors described in Table 2 below.
The expression of at least some of these fourteen factors in the Oct4KICD45+A cells resulted in colonies with typical morphology of pluripotent cells, such as human ES cells (
In this embodiment, EGFP expression occurs when the native Oct4 promoter/regulatory region is active. In other words, undifferentiated cells are identified by a green color that disappears when the cells differentiate. Thus, the expression of endogenous Oct-4 in the primate ES cells was selectable. These colonies also expressed Oct-4, SSEA3, SSEA4, Tra-1-60 and Tra-1-81 pluripotent cell-specific markers (
Inventors randomly picked six colonies from two separate transfections with the same pool of fourteen ES cell-enriched potency-determining factors, and propagated five stable colonies for at least eight weeks. Thus, inventors identified a novel approach for reprogramming primate somatic cells to become higher potency cells by administering fourteen potency-determining factors into the somatic cells.
When these cells were exposed to other combinations of potency-determining factors (i.e., Sox2, c-Myc, Oct 3/4 and Klf4) using the lentiviral delivery system described herein, reprogramming and conversion of the cells were not observed.
Inventors used the techniques described herein to screen for subsets of the fourteen tested factors that are sufficient to reprogram the tested cells. Inventors' set of fourteen sufficient factors was subsequently narrowed to a set of six, and then four genes sufficient to reprogram these cells (
To identify a more limited set of potency-determining factors capable of reprogramming differentiated cells back to pluripotency, the above-identified methods were repeated with a combination of Pou5F1 (Oct-4), Nanog, Sox2 and Lin28. Inventors used the techniques described above to screen these potency-determining factors for their ability to reprogram cells.
A different cell type was used in this example to further demonstrate the utility of the methods. The cell type was a mesenchymal-like clonal cell directly differentiated from human H1 Oct4 knock-in ES cells, as described above. As used herein, “clonal” refers to a characteristic of a population of cells derived from a common ancestor (i.e., derived from a single cell, not derived from a cell aggregate). That is, in a “clonal population,” the cells display a uniform pattern of cell surface markers and morphological characteristics, as well as being substantially genetically identical.
Briefly, human H1 Oct4 knock-in ES cells (p76 to p110) were induced to differentiate in co-culture with mouse OP9 bone marrow stromal cells. See, Vodyanyk M, et al., Blood 105:617-626 (2005), incorporated herein by reference as if set forth in its entirety. Small aggregates of human H1 Oct4 knock-in ES cells were added to OP9 cells in alpha MEM supplemented with 10% FCS and 100 μM MTG (Sigma). On the next day (day 1) of culture, the medium was changed, and the cultures were harvested on the days indicated below.
On day 2 of co-culture, mesodermal commitment was detected by a peak expression of transcription factors for mesendoderm (GSC, MIXL1 and T (BRACHYURY)) and early mesoderm (EVX1, LHX1 and TBX6) with NimbleGen® (Madison, WI) microarrays. During days 3-5, specification of endoderm and mesodermal lineages was observed. This stage was accompanied with sustained expression of genes involved in epithelial-mesenchymal transition (EMT; SNAIL and SLUG) and cell expansion (HOXB2-3). It also coincided with a maximal cell proliferation rate in human H1 Oct4 knock-in ES cells/OP9 co-culture.
Differentiation of specific mesendodermal lineages was observed on days 5-7 of co-culture, when markers of developing endoderm (AFP and SERPINA1), mesenchymal (SOX9, RUNX2 and PPARG2) and hematoendothelial (CDH5 and GATA1) cells were detected. However, muscle-inductive factors (MYOD1, MYF5 and MYF6) were not expressed throughout seven days of co-culture. Moreover, neuroectoderm (SOX1 and NEFL) or trophectoderm (CGB and PLAC) markers were not detected, indicating that OP9 cells provided an efficient inductive environment for directed hESC differentiation toward the mesendodermal pathway.
Also on day 2, a single-cell suspension of the human ES cell-derived cells was harvested by successive enzymatic treatment with collagenase IV (Gibco-Invitrogen) at 1 mg/ml in DMEM/F12 medium for 15 minutes at 37° C. and 0.05% Trypsin-0.5 mM EDTA (Gibco-Invitrogen) for 10 minutes at 37° C. Cells were washed 3 times with PBS-5% FBS, filtered through 70 μM and 30 μM cell strainers (BD Labware; Bedford, MA) and labeled with anti-mouse CD29-PE (AbD Serotec; Raleigh, NC) and anti-PE paramagnetic monoclonal antibodies (Miltenyi Biotech; Auburn, CA). The cell suspension was purified with magnet-activated cell sorting (MACs) by passing it through a LD magnetic column attached to a Midi-MACS separation unit (Miltenyi Biotech) to obtain a negative fraction of OP9-depleted, human H1 Oct4 knock-in ES cell-derived cells. Purity of human H1 Oct4 knock-in ES cell-derived cells was verified using pan anti-human TRA-1-85 monoclonal antibodies (R&D Systems; Minneapolis, MN).
Purified human H1 Oct4 knock-in ES cell-derived cells were plated at density of 2×104 cells/ml on semisolid, serum-free medium composed of StemLine™ serum-free medium (Sigma) supplemented with 5-100 ng/ml basic fibroblast growth factor (bFGF; PeproTech; Rocky Hill, NJ) and 1% methylcellulose (StemCell Technologies, Inc.) with or without 10-20 ng/ml PDGF-BB (PeproTech). PDGF-BB improved growth of mesenchymal cells, but was not essential for colony formation. After 14-21 days of culture, large, compact mesenchymal colonies formed, resembling embryoid bodies (EBs). Mesenchymal colonies were detected on day 7; however, 14-21 days were required to reveal actively growing colonies.
Individual mesenchymal colonies were transferred to wells of a collagen- or fibronectin-coated, 96-well plate pre-filled with 0.2 ml/well StemLine® serum-free medium supplemented with 5-100 ng/ml bFGF. After 3-4 days of culture, adherent cells from individual wells were harvested by trypsin treatment and expanded on collagen- or fibronectin-coated dishes in StemLine® serum-free medium with 5-100 ng/ml bFGF.
Transgene-expressing lentiviral transduction was then carried out as described above. Inventors tested the hypothesis that differentiated mesenchymal-like cells could be reprogrammed to a state of pluripotency by expressing a limited set of potency-determining factors (e.g., Oct-4, Nanog, Sox2 and Lin28). The expression of at least these four potency-determining factors resulted in colonies having cells with typical morphology of pluripotent cells, such as human ES cells (
In this embodiment, EGFP expression occurred when the native Oct4 promoter/regulatory region was active. In other words, undifferentiated cells were identified by a green color that was absent from differentiated cells. Thus, the expression of endogenous Oct-4 in the cells was selectable. Reprogrammed colonies also expressed Oct-4, SSEA3, SSEA4, Tra-1-60 and Tra-1-81 pluripotent cell-specific markers (data not shown).
Inventors randomly picked six colonies from two separate transfections with the same pool of fourteen ES cell-enriched potency-determining factors, and propagated five stable colonies for at least eight weeks. Thus, inventors identified a novel approach for reprogramming primate somatic cells to become higher potency cells by administering four potency-determining factors into the somatic cells.
When these cells were exposed to other combinations of potency-determining factors (i.e., Sox2, c-Myc, Oct 3/4 and Klf4) using the lentiviral delivery system described herein, reprogramming and conversion of the cells were not observed.
To identify an even more limited set of potency-determining factors capable of reprogramming differentiated cells back to pluripotency, the above-identified methods were repeated in the mesenchymal-like cells of Example 3 with a combination of two of the following four potency-determining factors: Oct-4, Nanog, Sox2 and Lin28. Inventors used the techniques described above to screen these potency-determining factors for their ability to reprogram cells.
Transgene-expressing lentiviral transduction was then carried out as described above. Inventors tested the hypothesis that differentiated mesenchymal-like cells could be reprogrammed to a state of pluripotency by expressing fewer than four potency-determining factors. The expression of at least Oct-4 and Sox2 (
To further demonstrate the utility of the limited set of potency-determining factors in reprogramming differentiated cells back to pluripotency, the above-identified methods were repeated with ATCC Catalog No. CCL-186 (IMR-90; ATCC), which are human fetal lung fibroblast cells (see also, Birney E, et al., Nature 447:799-816 (2007)).
Transgene-expressing lentiviral transduction was carried out as described above. That is, IMR-90 cells (0.9×106/well), were transduced with a combination of Oct-4, Sox2, Nanog and Lin28. Inventors tested the hypothesis that differentiated fibroblast cells could be reprogrammed to a state of pluripotency by expressing a limited set of potency-determining factors (e.g., Oct-4, Sox2, Nanog and Lin28). Following transduction, cells were transferred to three 10-cm dishes seeded with irradiated mouse embryonic fibroblasts (MEFs). By day 12 post-transduction, small colonies with human ES cell morphology became visible. On day 20 post-transduction, a total of 198 colonies were visible on 3 plates. Forty-one of the colonies were picked, thirty-five of which were successfully expanded for an additional three weeks. Six of these colonies were then selected for continued expansion and analysis, and the other twenty-nine were frozen.
The introduction of at least Oct-4, Sox2, Nanog and Lin28 resulted in colonies with typical morphology of pluripotent cells like human ES cells that had a normal karyotype. Cells from each colony likewise expressed telomerase activity and expressed human ES cell-specific surface antigens (i.e., SSEA-3, SSEA-4, Tra-1-60 and Tral-81). For each of the colonies, the expression of endogenous OCT4 and NANOG was at levels similar to that of pluripotent cells, although the exogenous expression of these genes did vary. Moreover, EB and teratoma formation demonstrated that the reprogrammed cells had a developmental potential to give rise to differentiated derivatives of all three primary germ layers.
DNA fingerprint analysis confirmed that these colonies were derived from IMR-90 cells and that they were not derived from human ES cells lines (e.g., H1, H7, H9, H13 and H14).
Similar to the data obtained with differentiated mesenchymal cells, the greatest number of colonies having cells with typical morphology of pluripotent cells, such as human ES cells was obtained using the full complement of Oct-4, Nanog, Sox2 or Lin28. However, when Oct-4, Nanog, Sox2 or Lin28 were absent, the number of ES-like colonies was significantly attenuated (e.g., Nanog or Lin28) or absent (e.g., Oct-4 or Sox2).
The colonies selected for expansion and detailed characterization proliferated for at least twelve weeks and retained typical characteristics of normal pluripotent cells, even though no selection for the activation of a pluripotency-specific gene was applied during reprogramming.
Reprogrammed cells were identified based on morphology alone (i.e., having a compact colony with high nucleus to cytoplasm ratio and prominent nucleolus). Reprogrammed cells also expressed Oct-4, SSEA3, SSEA4, Tra-1-60 and Tra-1-81 pluripotent cell-specific markers.
To further demonstrate the utility of the limited set of potency-determining factors in reprogramming differentiated cells back to pluripotency, the above-identified methods were repeated with the IMR-90 cells, described above. In this set of experiments, fewer potency-determining factors were used than in Example 5.
Transgene-expressing lentiviral transduction was carried out as described above. IMR-90 cells were transduced with a combination of three of the following: Oct-4, Sox2, Nanog and Lin28. Inventors tested the hypothesis that differentiated fibroblast cells could be reprogrammed to a state of pluripotency by expressing the even more limited set of potency-determining factors. The expression of at least three factors resulted in colonies with typical morphology of pluripotent cells like human ES cells. Reprogrammed colonies having cells with typical morphology of pluripotent cells were obtained using the full complement of Oct-4, Sox2 and Nanog with or without Lin28. Therefore, the presence or absence of Lin28 did not affect reprogramming. However, when any of Oct-4, Nanog or Sox2 was absent, the number of reprogrammed colonies was significantly attenuated or absent.
To examine for the presence of Oct-4, Sox2, Nanog and Lin28 provirus in the reprogrammed cells, PCR with transgene-specific primer pairs (see, Table 3; one gene-specific primer and one lentiviral vector-specific primer) was carried out using genomic DNA from IMR-90 clones as template. The reactions employed the pfx DNA polymerase (Invitrogen, amplification buffer was used at 2×, and enhancer solution was used at 3×), and the following conditions: initial denaturation for 1 minute at 95° C.; 35 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 68° C. for 2 minutes; and followed by 68° C. for 7 minutes. PCR analysis for the transgenes showed that either all four transgenes or three transgenes (i.e., Oct-4, Sox2 and Nanog) integrated into the pluripotent cells following exposure to transgene-expressing lentivirus vectors.
Reprogrammed cells were identified based on morphology alone (i.e., having a compact colony with high nucleus to cytoplasm ratio and prominent nucleolus). Reprogrammed cells also expressed Oct-4, SSEA3, SSEA4, Tra-1-60 and Tra-1-81 pluripotent cell-specific markers.
To further demonstrate the utility of the limited set of potency-determining factors in reprogramming differentiated cells to pluripotency, the above-identified methods were repeated with ATCC Catalog No. CRL-2097 (ATCC), which are human post-natal foreskin fibroblast cells.
Transgene-expressing lentiviral transduction was carried out as described above. Post-natal fibroblast cells (0.6×106/well) were transduced with a combination of Oct-4, Sox2, Nanog and Lin28. Inventors tested the hypothesis that differentiated, post-natal, fibroblast cells could be reprogrammed to a state of pluripotency by expressing a limited set of potency-determining factors and obtained promising results. Following transduction, cells were transferred to three 10-cm dishes seeded with irradiated MEFs. By day 15 post-transduction, small colonies with pluripotent cell morphology became visible. On day 20 post-transduction, a total of 57 colonies were visible on the plates. Twenty-nine of the colonies were picked, twenty-seven of which were successfully expanded for an additional three weeks. Four of these colonies were then selected for continued expansion and analysis, and the other twenty-three were frozen.
The expression of Oct-4, Sox2, Nanog and Lin28 resulted in colonies having cells with typical morphology of pluripotent cells, such as human ES cells, and a normal karyotype. Reprogrammed colonies likewise expressed telomerase activity and expressed pluripotent cell-specific markers (i.e., SSEA-3, SSEA-4, Tra-1-60 and Tral-81). For each, endogenous OCT4 and NANOG was expressed at levels similar to that observed in human pluripotent cells, although the exogenous expression of these genes varied. Moreover, EB and teratoma formation demonstrated that the reprogrammed cells had a developmental potential to give rise to differentiated derivatives of all three primary germ layers. However, in contrast to the iPS cells obtained from IMR-90 cells, iPS cells derived from CRL-2097 cells showed a variation in the lineages apparent in teratomas examined at five weeks. Two of the iPS cell colonies showed neural differentiation; whereas the other two colonies showed multiple foci of columnar epithelial cells, reminiscent of primitive ectoderm.
DNA fingerprint analysis confirmed that these colonies were derived from the original cell line and confirmed that they were not derived from human ES cells lines (e.g., H1, H7, H9, H13 and H14).
Similar to the data obtained after transduction of differentiated mesenchymal cells, the greatest number of colonies having cells with typical morphology of human pluripotent cells were obtained using the full complement of Oct-4, Sox2, Nanog and Lin28. Interestingly, one cell line lacked Lin28, confirming that Lin28 was not essential for reprogramming somatic cells.
The colonies selected for expansion and detailed characterization proliferated for at least twelve weeks and retained typical characteristics of normal human pluripotent cells, even though no selection for the activation of a pluripotency-specific gene was applied during reprogramming.
Reprogrammed cells were identified based on morphology alone (i.e., having a compact colony with high nucleus to cytoplasm ratio and prominent nucleolus). Reprogrammed cells also expressed Oct-4, SSEA3, SSEA4, Tra-1-60 and Tra-1-81 pluripotent cell-specific markers.
When these cells were exposed to other combinations of factors (i.e., Sox2, c-Myc, Oct 3/4 and Klf4) using the lentiviral delivery system described herein, reprogramming and conversion of the cells were not observed.
To further demonstrate the utility of the limited set of potency-determining factors in reprogramming differentiated cells to pluripotency, the above-identified methods were repeated with ATCC Catalog No. CRL-2106 (SK46; ATCC), which are human adult skin cells.
Transgene-expressing lentiviral transduction was carried out as described above. That is, skin cells (2.0×105/well) were transduced with a combination of Oct-4, Sox2, Nanog and Lin28. Inventors tested the hypothesis that adult skin cells could be reprogrammed to a state of pluripotency by expressing a limited set of potency-determining factors and obtained promising results. Following transduction, cells were transferred to three 10-cm dishes seeded with irradiated mouse embryonic fibroblasts (MEFs). After 10 days in human ES cell culture medium human ES cell culture medium conditioned with irradiated MEFs was used to support cell growth. By day 18 post-transduction, small colonies with pluripotent cell morphology became visible.
The expression of Oct-4, Sox2, Nanog and Lin28 resulted in colonies having cells with typical morphology of pluripotent cells (see,
To increase the reprogramming efficiency, the above-identified methods were repeated using the construct shown in
Transgene-expressing lentiviral transduction was carried out as described above. That is, 293FT cells or mesenchymal cells (˜2×105 cells/well of 6-well plate, seeded overnight) were transduced with various transgene combinations. Cells were transferred to 10 cm MEF dish (1 well of 6-well plate to 1×10 cm MEF dish) following the overnight incubation with lentivirus. Geneticin selection (50 μg/ml) for an active, endogenous, OCT4 promoter was carried out between day 11 to 15 post transduction. iPS colonies were counted on day 16.
It is understood that certain adaptations of the invention described in this disclosure are a matter of routine optimization for those skilled in the art, and can be implemented without departing from the spirit of the invention, or the scope of the appended claims.
All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. It is understood, however, that examples and embodiments of the present invention set forth above are illustrative and not intended to confine the invention. The invention embraces all modified forms of the examples and embodiments as come within the scope of the following claims.
This application is a continuation of U.S. patent application Ser. No. 16/137,899, filed Sep. 21, 2018, which is a continuation of U.S. patent application Ser. No. 13/793,594, filed Mar. 11, 2013, which is a continuation of U.S. patent application Ser. No. 12/053,440, filed Mar. 21, 2008, which claims the benefit of U.S. Provisional Patent Application No. 60/919,687, filed Mar. 23, 2007; U.S. Provisional Patent Application No. 60/974,980, filed Sep. 25, 2007; and U.S. Provisional Patent Application No. 60/989,058, filed Nov. 19, 2007, each of which is incorporated herein by reference as if set forth in its entirety.
This invention was made with government support under RR000167 and GM069981 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5925565 | Berlioz et al. | Jul 1999 | A |
| 5935819 | Eichner et al. | Aug 1999 | A |
| 6060273 | Wilhelm et al. | May 2000 | A |
| 7465580 | Sugden et al. | Dec 2008 | B2 |
| 7682828 | Jaenisch et al. | Mar 2010 | B2 |
| 8058065 | Yamanaka et al. | Nov 2011 | B2 |
| 8183038 | Thomson | May 2012 | B2 |
| 8211697 | Sakurada et al. | Jul 2012 | B2 |
| 8278104 | Yamanaka et al. | Oct 2012 | B2 |
| 8440461 | Thomson | May 2013 | B2 |
| 8546140 | Mack et al. | Oct 2013 | B2 |
| 9499786 | Thomson | Nov 2016 | B2 |
| 10106772 | Thomson | Oct 2018 | B2 |
| 20020090722 | Dominko et al. | Jul 2002 | A1 |
| 20020136709 | Zahner et al. | Sep 2002 | A1 |
| 20040199935 | Chapman | Oct 2004 | A1 |
| 20050079616 | Reubinoff | Apr 2005 | A1 |
| 20050255573 | Chambers et al. | Nov 2005 | A1 |
| 20060110830 | Dominko et al. | May 2006 | A1 |
| 20060128018 | Zwaka et al. | Jun 2006 | A1 |
| 20060160218 | Slack et al. | Jul 2006 | A1 |
| 20060263882 | Fazio et al. | Nov 2006 | A1 |
| 20080003560 | Nakatsuji et al. | Jan 2008 | A1 |
| 20090081784 | Vodanyk | Mar 2009 | A1 |
| 20100015705 | Vodyanyk | Jan 2010 | A1 |
| 20100041054 | Mack | Feb 2010 | A1 |
| 20100261274 | Vodyank | Oct 2010 | A1 |
| 20100279404 | Yamanaka et al. | Nov 2010 | A1 |
| 20100285589 | Lowry et al. | Nov 2010 | A1 |
| 20110217274 | Reid | Sep 2011 | A1 |
| 20130189778 | Mack | Jul 2013 | A1 |
| 20130210138 | Thomson et al. | Aug 2013 | A1 |
| 20130217117 | Thomson et al. | Aug 2013 | A1 |
| 20140038293 | Mack | Feb 2014 | A1 |
| 20140057355 | Thomson et al. | Feb 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 2660123 | Apr 2009 | CA |
| 2632142 | Aug 2013 | CA |
| 1698639 | Sep 2006 | EP |
| 2048229 | Apr 2009 | EP |
| 2053128 | Apr 2009 | EP |
| 2072618 | Jun 2009 | EP |
| 2008-502644 | Mar 1996 | JP |
| 2007-209240 | Aug 2007 | JP |
| 2007-535923 | Dec 2007 | JP |
| 2008-067693 | Mar 2008 | JP |
| 2007-525975 | Dec 2013 | JP |
| 1996022362 | Feb 1996 | WO |
| 2005072129 | Aug 2005 | WO |
| 2005108585 | Nov 2005 | WO |
| 2007027156 | Mar 2007 | WO |
| 2007047766 | Apr 2007 | WO |
| 2007069666 | Jun 2007 | WO |
| 2007069666 | Jun 2007 | WO |
| 2008013067 | Jan 2008 | WO |
| 2008013737 | Jan 2008 | WO |
| 2008020815 | Feb 2008 | WO |
| 2008033469 | Mar 2008 | WO |
| 2008118820 | Oct 2008 | WO |
| 2009032194 | Mar 2009 | WO |
| 2009032456 | Mar 2009 | WO |
| 2009061442 | May 2009 | WO |
| 2009091543 | Jul 2009 | WO |
| 2009092042 | Jul 2009 | WO |
| 2009133971 | Nov 2009 | WO |
| 2009149233 | Dec 2009 | WO |
| 2010012077 | Feb 2010 | WO |
| 2010028019 | Mar 2010 | WO |
| Entry |
|---|
| Okita (Science, Nov. 7, 2008, vol. 322, p. 949-953). |
| Gonzalez (PNAS, Jun. 2, 2009, vol. 106, No. 22, p. 8918-8922). |
| Bilic (Stem Cells, 2012, vol. 30, p. 33-41). |
| Kennedy and Sugden, “EBNA-1, a bifunctional transcriptional activator,” Mol. And Cell. Biol., 23(19):6901-6908, 2003. |
| Leight and Sugden, “Establishment of an oriP replicon is dependent upon an infrequent, epigenetic event,” Mol. and Cell. Biol., 21(13):4149-4161, 2001. |
| Kennedy et al., “Epstein-Barr virus provides a survival factor to Burkitt's lymphomas,” PNAS, 100:14269-14274,2003. |
| Kim et al., “Construction of a bifunctional mRNA in the mouse by using the internal C84. ribosomal entry site ofthe encephalomyocarditis virus,” Mol. Cellular Biol., 12 (8): 3636-3643, 1992. |
| Kim et al., “Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors,” Nature, 454:646-650, 2008. |
| Liao et al., “Enhanced efficiency of generating induced pluripotent stem (iPS) cells from C86. human somatic cells by a combination of six transcription factors,” Cell Research, 18:600-603, 2008. |
| Lindner and Sugden, “The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient licensed, extrachromosomal replication in human cells,” Plasmid, 58 (1 ): 1-12, 2007. |
| Lois et al., “Germline transmission and tissue-specific expression oftransgenes delivered by lentiviral vectors,” Science, 295:868-872, 2002. |
| Lowry et al., “Generation of human induced pluripotent stems cells from dermal fibroblasts,” PNAS, 105(8):2883-2888, 2008. |
| Macejak and Sarnow, “Internal initiation of translation mediated by the 5′ leader of a cellular mRNA,” Nature, 353(6339): 90-94, 1991. |
| Stadtfeld et al., “Induced pluripotent stem cells generated without viral integration,” Science, 322 (5903): 945-949, 2008. |
| Mackey and Sugden, “The linking regions ofEBNA 1 are essential for its support of replication and transcription,” Mol. Cell. Biol., 19(5):3349-3359, 1999. |
| Mali et al. Improved Efficiency and Pace of Generating Induced Pluripotent Stem Cells from Human Adult and Fetal Fibroblasts. Stem Cells, 2008, vol. 26, pp. 1998-2005. |
| Manzini et al., “Genetically modified pigs produced with a nonviral episomal vector,” PNAS, 103(47):17672-17677, 2006. |
| McBratney et al., “Internal initiation oftranslation,” Curr. Opin. Cell Biol., 5 (6): 961-965, 1993. |
| Mikkelsen et al., “Dissecting direct reprogramming through integrative genomic analysis,” Nature, 454: 49-56, 2008. |
| Nanbo et al., “The coupling of synthesis and partitioning ofEBV's plasmid replicon is revealed in live cells,” The EMBO Journal, 26(19):4252-4562, 2007. |
| Oster et al., “Myc is an essential negative regulator of platelet-derived grow1h factor beta receptor expression,” Mol. Cell. Biology, 20(18):6768-6778, 2000. |
| Papapetrou et al., “Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-C99. Myc expression for efficient human iPSC induction and differentiation,” PNAS Early Edition. Published online before print Jun. 23, 2009, doi: 10.1073/pnas.0904825106. |
| Park et al., “Disease-specific induced pluripotent stem cells,” Cell., 134:877-886, 2008. |
| Park et al., “Generation of human-induced pluripotent stem cells,” Nature Protocols, 3:1180-1186,2008. |
| Pelletier and Sonenberg, “Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA,” Nature, 334 (6180): 320-325, 1988. |
| Piechaczek et al., “A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells,” Nucleic Acids Res., 27(2):426-428, 1999. |
| Provost et al., “Viral 2A peptides allow expression of multiple proteins from a single ORF in transgenic zebrafish embryos,” Genesis, 45 (10): 625-629,2007. |
| Rao, et al. “Assessing iPSC Reprogramming Methods for Their Suitability in Translational Medicine,” J Cell Biochem. Oct. 2012; 113(10): 3061-3068. |
| Pera, Reijo et al., “Gene expression profiles of human inner cell mass cells and embryonic stem cells,” Differentiation, 78(1 ):18-23, 2009. |
| Reubinoff et al., “Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro,” Nature Biotechnology, 18:399-404, 2000. |
| Schaarschmidt et al., “An episomal mammalian replicon: sequence-independent binding of the origin recognition complex,” EMBO J, 23(1 ):191-201, 2004. |
| Sears et al., “The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning oflatent EBV genomes by tethering them to cellular chromosomes,” J Virol., 78(21):11487-11505, 2004. |
| Shao et al., “Generation of iPS cells using defined factors linked via the self-cleaving 2A sequences in a single open reading frame,” Cell Research, 19:296-306, 2009. |
| Shi et al., “A combined chemical and genetic approach for the generation of induced pluripotent stem cells,” Cell Stem Cell, 2:525-528, 2008. |
| Sommer et al., “Induced pluripotent stem cell generation using a single lentiviral stem cell cassette,” Stem Cells, 27:543-549, 2009. |
| Stadtfeld et al., “Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse,” Cell Stem Cell, 2:230-240, 2008. |
| Stojkovic and Phinney, “Programming battle: egg vs. virus,” Stem Cells Express, available on line at http://stemcells.alphamedpress.org/cgi/content/full/26/1/1, Nov. 29, 2007. |
| Takahashi, et al. Induced pluripotent stem cells in medicine and biology, Development 140:2457 (2013). |
| Tanabe et al., “Historical overview and future prospects of the iPS cells,” Regeneration Medicine, 7(2):83-89, 2008. [Japanese only]. |
| Warren et al., “Highly efficient reprogramming to pluripotency and directed differentiation ofhuman cells with synthetic modified mRNA,” Cell Stem Cell, 7:1-13, 2010. |
| Wernig et al., “A drug-inducible transgenic system for direct reprogramming of multiple somatc cell types,” Nature Biotechnology, 26:916-924, 2008. |
| Wernig et al., “C-Myc is dispensable for direct reprogramming of mouse fibroblasts,” Cell Stem Cell, 2(1 ):10-12, 2008. |
| Woltejen et al., “piggyBAC transposition reprograms fibroblasts to induce pluripotent stem cells,” Nature, 458(7239):766-770, 2009. |
| Yates et al., “A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells,” Proc. Natl. A cad. Sci. USA, 81 :3806-3810, 1984. |
| Yeom et al., “Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells,” Development, 122:881-894, 1996. |
| Yoshimizu et al., “Germ line-specific expression of the Oct-4/green fluorescent protein (GFP) transgene in mice,” Develop. Growth. Dill, 41 :675-684, 1999. |
| Yu et al., Supporting Online Material for: “Induced pluripotent stem cell lines derived from human somatic cells,” Science, available at http://www.sciencemag.org/cgi/data/1151526/DCI/2, Nov. 20, 2007. |
| Telugu, et al. “Porcine induced pluripotent stem cells analogous to naive and primed embryonic stem cells of the mouse” Int. J. Dev. Biol. 54: 1703-1711 (2010). |
| Zhang Efficient Reprogramming of Naive-Like Induced Pluripotent Stem Cells from Porcine Adipose-Derived Stem Cells with a Feeder-Independent and Serum-Free System???????????? |
| Office Action issued in U.S. Appl. No. 12/478,154, dated Dec. 29, 2010. |
| Office Action issued in U.S. Appl. No. 12/478,154, dated Jul. 20, 2011. |
| Office Action issued in U.S. Appl. No. 12/478,154, dated Mar. 29, 2011. |
| Office Action issued in U.S. Appl. No. 12/478,154, dated May 2, 2013. |
| Van Craenenbroeck, et al. Episomal vectors for gene expression in mammalian cells, Eur. J. Biochem. 267, 5665-5678 (2000). |
| Okita, et al., Generation of mouse induced pluripotent stem cells without viral vectors, (Science, Nov. 7, 2008, vol. 322, p. 949-953). |
| Yamanaka, S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Proliferation, 2008, vol. 41, pp. 51-56. |
| Gonzales et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. PNAS, 2009, vol. 106, pp. 8918-8922. |
| Rodriguez et al. Manipulation of OCT4 Levels in Human Embryonic Stem Cells Results in Induction of Differential Cell Types. Experimental Biology and Medicine, 2007, vol. 232, pp. 1368-1380. |
| “pBABE-MN-IRES-E-GFP,” vector information accessed online at C64. http:/ /www.lablife.org/p?a=vdb view &id=g2.CylnpjjVjRDXWTUliXTHEX8hmrO-, on Jan. 24, 2011. |
| “pBluescript II XR predigested vector,” instruction manual accessed at http:/ /www.genomics.agilent.com/files/Manual/212240.pdf on Jan. 24, 2011. |
| “piRES2-EGFP vector information,” accessed at www.clontech.com on Jan. 24, 2011. |
| “pLIB vector information,” accessed online at www.clontech.com on Jan. 24, 2011. |
| “pMXs retroviral vector data sheet,” accessed on line at www.cellbiolabs.com on Jan. 21, 2011. |
| “pMX-STAT5A(1 *6) Retroviral Vector,” Cell Biolabs, Inc., available at http://www. cellbio labs. com, 2008. |
| Almqvist et al., “Functional interaction of Oct transcription factors with the family of repeats in Epstein-Barr virus oriP,” J of General Virology, 86 (Part 5): 1261-1267, 2005. |
| Altmann et al., “Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes,” PNAS, 103(38):14188-14193, 2006. |
| Baer et al., “Transcriptional properties of genomic transgene integration sites marked by electroporation or retroviral infection,” Biochemistry, 39:7041-7049, 2000. |
| Baker, “A conversation with Shinya Yamanaka, Professor at Kyoto University,” Nature Reports Stem Cells, pp. 1-2, published online Jun. 7, 2007, accessed online at http://www.nature.com/stemcells/2007/0706/070607/full/stemcells.2007.9.html on Oct. 18, 2012. |
| Baker, “Reprogramming kinetics,” Nature Reports Stem Cells, available at http://www. nature. com/stemcells/2008/0803/0 803 06/ full/ stemcells.2008.44.html, published on line Mar. 6, 2008. |
| Lewitzky and Yamanaka, “Reprogramming somatic cells towards pluripotency by defined factors,” Current Opinion in Biotechnology, 18:467-473, 2007. |
| Blelloch et al., “Generation of induced pluripotent stem cells in the absence of drug selection,” Cell Stem Cell, 1:245-247,2007. |
| Bingham, “Cosuppression comes to the animals,” Cell, 90(3):385-387, 1997. |
| Bode et al., “The hitchhiking principle: Optimizing episomal vectors for the use in gene therapy and biotechnology,” Gene Ther. Mol. Biol., 6:33-46, 2001. |
| Bode et al., “The transgeneticist's toolbox: novel methods for the targeted modification of eukaryotic genomes,” Biol. Chem., 381:801-813, 2000b. |
| Boyer et al., “Core transcriptional regulatory circuitry in human embryonic stem cells,” Cell, 122(6):947-56, 2005. |
| Brambrink et al., “Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells,” Cell Stem Cell, 7(2):151-159, 2008. |
| Calos et al., “Stability without a centromere,” PNAS, 95:4084-4085, 1998. |
| Carey et al., “Reprogramming of murine and human somatic cells using a single polycistronic vector,” PNAS USA, 106(1): 157-162,2009. |
| Chang et al., “Polycistronic lentiviral vectore for “Hit and Run” reprogramming of adult skin fibroblasts to induced pluripotent stem cells,” Stem Cells, 27: 1042-1049, 2009. |
| Chou, et al. “Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures” Cell Research 21 :518 (2011 ). |
| Conese, et al: Gene therapy progress and prospects: Episomally maintained self-replicating systems, Gene Therapy, Dec. 2004, pp. 1735-1741, vol. 11, No. 24. |
| Cox and Rizzino, “Induced pluripotent stem cells: what lies beyond the paradigm shift,” Experimental Biology and Medicine, 235:148-158, 2010. |
| Egli et al., “Mediators of reprogramming: transcription factors and transitions through mitosis,” Moecular Cell Biology, 9:505-516, 2008. |
| Fellner, T. “Building Bridges from Research to Therapy: Development of Novel Technologies for the Generation of Defined and cGMP-compliant iPSCs” Bio-Trac/ NIH CRM Stem Cell Industry Symposium May 29, 2013 at Third Party Requestor Lonza Walkersville, Inc. (Walkersville, MD). |
| Garrick et al., “Repeat-induced gene silencing in mammals,” Nat. Genet., 18:56-59, 1998. |
| Graham et al., “SOX2 functions to maintain neural progenitor identity,” Neuron, 39:749-765, 2003. |
| Hanna et al., “Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency,” Cell, 133:250-264, 2008. |
| Hanna et al., “Reprogramming of somatic cell identity,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 73: 147-155,2008. |
| Hartenbach et al., “Autoregulated, bidirectional and multicistronic gas-inducible mammalian as well as lentiviral expression vectors,” Journal of Biotechnology, 120:83-98,2005. |
| He et al., “A simplified system for generating recombinant adenoviruses,” PNAS, 95:2509-2514, 1998. |
| Hermeking et al., “Identification of CDK4 as a target of c-MYC,” PNAS, 97(5):2229-2234, 2000. |
| Huangfu et al., “Induction of pluripotent stem cells by defined factors in greatly improved by small-molecule compounds,” Nature Biotechnology, 26:795-797, 2008. |
| Hung et al., “Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBVC13. encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by highmobility group-I or histone H1 ,” PNAS, 98(4):1865-1870, 2001. |
| Jaenisch, “Transgenic animals,” Science, 240 (4858): 1468-1474, 1988. (00192510). |
| Jenke et al., “Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome,” PNAS, 101 (31 ), 11322-11327,2004. |
| Jha et al., “SV 40-mediated immortalization,” Experimental Cell Res., 245(1 ): 1-7, 1998. |
| Jia et al., “A nonviral minicircle vector for deriving human iPS cells,” Nature Methods, 7(3):197-199, 2010. |
| Kabouridis, “Biological applications of the protein transduction technology,” Trends in Biotechnology, 21 (11 ):498-503, 2003. |
| Kaji et al., “Virus-free induction of pluripotency and subsequent excision of reprogramming factors,” Nature, 458 (7239):771-775, 2009. |
| Kameda, T. et al., “A severe de novo methylation of episomal vectors by human ES cells” Biochem. Biophys. Res. Comm. 349:1269 (2006). |
| Kaufman et al., “Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells,” The EMBO Journal, 6:187-193, 1987. |
| Office Action issued in U.S. Appl. No. 12/478,154, dated Oct. 23, 2012. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated Feb. 29, 2012. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated Jan. 28, 2011. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated May 24, 2013. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated May 31, 2011. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated Oct. 19, 2010. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated Oct. 24, 2012. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated Sep. 24, 2014. |
| Office Action issued in U.S. Appl. No. 12/539,366, dated Sep. 21, 2011. |
| Office Action issued in U.S. Appl. No. 12/605,220, dated Feb. 10, 2012. |
| Office Action issued in U.S. Appl. No. 12/605,220, dated May 13, 2011. |
| Office Action issued in U.S. Appl. No. 12/727,061, dated Jun. 15, 2011. |
| Office Action issued in U.S. Appl. No. 13/607,072, dated Dec. 24, 2013. |
| Office Action issued in U.S. Appl. No. 13/607,072, dated Jul. 17, 2014. |
| Office Action issued in U.S. Appl. No. 13/766,100, dated Nov. 10, 2014. |
| Office Action issued in U.S. Appl. No. 13/793,594, dated Jun. 19, 2014. |
| Office Action issued in U.S. Appl. No. 13/794,297, dated Dec. 2, 2014. |
| Office Communication issued in Australian Patent Application No. 2009256202 dated Apr. 29, 2014. |
| Office Action issued in Canadian Application No. 2,734, 128, dated May 5, 2014. |
| Office Action issued in Chinese Application No. 200980138340.8, dated Mar. 7, 2013. |
| Office Action issued in European Application No. 09759392.5, dated Jun. 1, 2011. |
| Office Action issued in European Application No. 09759392.5, dated Sep. 5, 2014. |
| Office Action issued in European Application No. 09791378.4, dated Oct. 14, 2014. |
| Office Action issued in Japanese Application No. 2011-512634, dated Nov. 10, 2014. |
| Office Action issued in Japanese Application No. 2011-512634, dated Dec. 20, 2013. |
| Office Action issued in Japanese Application No. 2011-523094, dated Jan. 17, 2014. |
| Office Action issued in Japanese Application No. 2011-523094, dated Sep. 19, 2014 [English translation only]. |
| Office Action issued in U.S. Appl. No. 12/053,440, dated Dec. 17, 2010. |
| Office Action issued in U.S. Appl. No. 12/053,440, dated Dec. 18, 2012. |
| Office Action issued in U.S. Appl. No. 12/053,440, dated Jun. 18, 2010. |
| Office Action issued in U.S. Appl. No. 12/053,440, dated Jul. 25, 2012. |
| Office Action issued in U.S. Appl. No. 12/053,440, dated May 20, 2011. |
| Third Declaration of Amanda Mack filed in the prosecution of U.S. Appl. No. 12/478,154, filed Jun. 28, 2013. |
| U.S. Appl. No. 61/136,615, filed Sep. 19, 2008, by Yamanaka, et al. |
| U.S. Appl. No. 61/071,508, filed May 2, 2008, by Yamanaka, et al. |
| U.S. Appl. No. 61/136,246, filed Aug. 21, 2008, by Yamanaka, et al. |
| U.S. Appl. No. 61/058,858, filed Jun. 4, 2008, by Mack. |
| PCT International Preliminary Report on Patentability, issued in International Application No. PCT/US2009/046209, dated Dec. 16, 2010. |
| PCT International Search Report and Written Opinion, issued in International Application C102. No. PCT/US2009/053403, dated Dec. 2, 2009. |
| Yu et al. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. Science, 2009, vol. 324, pp. 797-802. |
| Jackson et al., Designing Nonviral Vectors for Efficient Gene Transfer and long-Term Gene Expression, Perspectives of Gene Therapy in Stem Cell Tissue Engineering, Molecular Therapy, 2006; 14(5): 613-626. |
| Goessler et al., Perspectives of Gene Therapy in Stem Cell Tissue Engineering, Cells Tissues Organs, 2006, 183(4): 169-179. |
| Polesskaya et al., Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency, Genes Dev. 2007; 21: 1125-1138. |
| Yu et al., Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells, Science 2007; 318(5858):1917-1920; published Nov. 20, 2007. |
| Park et al., Reprogramming of human somatic cells to pluripotency with defined factors, Nature 2008; 451: 141-146; Jan. 10, 2008. |
| Ren et al., Establishment and Applications of Epstein-Barr Virus-Based Episomal Vectors in Human Embryonic Stem Cells, Stem Cells 2006; 24: 1338-1347. |
| Liu et al., Maintenance of Pluripotency in Human Embryonic Stem Cells Stably Over-expressing Enhanced Green Fluorescent Protein, Stem Cells Dev., 2004, 13(6): 636-645. |
| Okita et al., Generation of⋅ germ-line competent induced pluripotent stem cells., Nature, 2007, 448:313-317. |
| Nishikawa, Reprogramming by the numbers, Nature Biotechnology, 2007; 25(8): 877-878; published Aug. 2007. |
| Hellen et al., Translation of encephalomyocarditis virus RNA by internal ribosomal entry., Curr Top MicrobiolImmunol, 1995; 203:31-63 (abstract only). |
| Alberio, et al., Reprogramming Somatic Cells Into Stem Cells, Reproduction, 2006, 132:709-720. |
| Amit, et al., Clonally Derived Human Embryonic Stem Cell Lines Maintain Pluripotency and Proliferative Potential for Prolonged Periods of Culture, Developmental Biology, 2000, 227:271-278. |
| Aoi, et al., Generation of Pluripotent Stem Cells From Adult Mouse Liver and Stomach Cells, Science, 2008, 321(5889):699-702. |
| Avilion, et al., Multipotent Cell Lineages in Early Mouse Development Depend on SOX2 Function, Genes & Development, 2003, 17:126-140. |
| Chambers, et al., Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells, Cell, 2003, 113:643-655. |
| Cibelli, et al., Cellular Reprogramming for the Creation of Patient-Specific Embryonic Stem Cells, Stem Cell Reviews, 2006, 2:289-296. |
| Collas, Dedifferentiation of Cells: New Approaches, Cytotherapy, 2007, 9(3):236-244. |
| Cowan, et al., Nuclear Reprogramming of Somatic Cells After Fusion With Human Embryonic Stem Cells, Science, 2005, 309:1369-1373. |
| Egli, et al., Developmental Reprogramming After Chromosome Transfer Into Mitotic Mouse Zygotes, Nature, 2007, 447:679-685. |
| Fackler, Scientist at Work/ Shinya Yamanaka—Risk Taking Is In His Genes, The New York Times, Dec. 11, 2007, 4 pages. |
| Frolov, et al., Alphavirus-Based Expression Vectors: Strategies and Applications, Proc. Natl. Acad. Sci. USA, 1996, 93:11371-11377. |
| Gao, et al., Nonviral Gene Delivery: What We Know and What Is Next, AAPS Journal, 2007, 9(1 ):E92-E104. |
| Ivanova, et al., Dissecting Self-Renewal in Stem Cells With RNA Interference, Nature, 2006, 442:533-538. |
| Ludwig, et al., Feeder-Independent Culture of Human Embryonic Stem Cells, Nature Methods, 2006, 3(8):637-646. |
| Ludwig, et al., Derivation of Human Embryonic Stem Cells in Defined Conditions, Nature Biotechnology, 2006, 24(2): 185-187. |
| Maherali, et al., Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling and Widespread Tissue Contribution, Cell Stem Cell, 2007, 1: 55-70. |
| Masaki, et al., Heterogeneity of Pluripotent Marker Gene Expression in Colonies Generated in Human iPS Cell Induction Culture, Stem Cell Research, 2008, 1(2):105-115. |
| Meissner, et al., Direct Reprogramming of Genetically Unmodified Fibroblasts Into Pluripotent Stem Cells, Nature Biotechnology, 2007, 25(10):1177-1181. |
| Milanesi, et al., BK Virus-Plasmid Expression Vector That Persists Episomally in Human Cells and Shuttles Into Escherichia coli, Molecular and Cellular Biology, 1984, 4(8):1551-1560. |
| Nakagawa, et al., Generation of Induced Pluripotent Stem Cells Without Myc From Mouse and Human Fibroblasts, Nature Biotechnology, 2008, 26(1 ):101-106. |
| Nichols, J., et al., Formation of Pluripotent Stem Cells in the Mammalian Embryo Depends on the POU Transcription Factor Oct4, Cell, 1998, 95:379-391. |
| Nichols, W., et al., Characterization of a New Human Diploid Cell Strain, IMR-90, Science, 1977, 196(4285):60-63. |
| Hochedlinger, et al., Nuclear Reprogramming and Pluripotency, Nature, 2006, 441:1061-1067. |
| Park, et al., Reprogramming of Human Somatic Cells to Pluripotency With Defined Factors, Nature, 2008, 451:141-146. |
| Pralong, et al., Cell Fusion for Reprogramming Pluripotency Toward Elimination of the Pluripotent Genome, Stem Cell Reviews, 2006, 2:331-340. |
| Ren, et al., Establishment of Human Embryonic Stem Cell Line Stably Expressing Epstein-Barr Virus-Encoded Nuclear Antigen 1, Acta Biochimica et Biophysica Sinica, 2005, 37(1 ):68-73. |
| Richards, et al., The Transcriptome Profile of Human Embryonic Stem Cells As Defined by SAGE, Stem Cells, 2004, 22:51-64. |
| Silva, et al., Nanog Promotes Transfer of Pluripotency After Cell Fusion, Nature, 2006, 441 :997-1001. |
| Takahashi, et al., Induction of Pluripotent Stem Cells From Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors, Cell, 2006, 126:663-676. |
| Takahashi, et al., Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors, Cell, 2007, 131:861-872. |
| Taranger, et al., Induction of Dedifferentiation, Genomewide Transcriptional Programming, and Epigenetic Reprogramming by Extracts of Carcinoma and Embryonic Stem Cells, Molecular Biology of the Cell, 2005, 16:5719-5735. |
| Thomson, et al., Embryonic Stem Cell Lines Derived from Human Blastocysts, Science, 1998, 282:1145-1147. |
| Vodyanik, et al., Human Embryonic Stem Cell-Derived CD34+ Cells: Efficient Production in the Coculture with OP9 Stromal Cells and Analysis of Lymphohematopoietic Potential, Blood, 2005, 105(2):617-626. |
| Wade-Martins, et al., Long-Term Stability of Large Insert Genomic DNA Episomal Shuttle Vectors in Human Cells, Nucleic Acids Research, 1999, 27(7):1674-1682. |
| Wernig, et al., In Vitro Reprogramming of Fibroblasts Into a Pluripotent ES-Cell-Like State, Nature, 2007, 448:318-324. |
| Yamanaka, et al., Strategies and New Developments in the Generation of Patient-Specific Pluripotent Stem Cells, Cell Stem Cell, 2007, 1(1):39-49. |
| Yu, et al., Human Embryonic Stem Cells Reprogram Myeloid Precursors Following Cell-Cell Fusion, Stem Cells, 2006, 24:168-176. |
| Yu, et al., Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells, Science, 2007, 318:1917-1920. |
| Zwaka, et al., Homologous Recombination in Human Embryonic Stem Cells, Nature Biotechnology, 2003, 21:319-321. |
| De Peppo GM et al, “Human embryonic mesodermal progenitors highly resemble human mesenchymal stem cells and display high potential for tissue engineering applications.”, Tissue Engineering. Part A (2010), vol. 16, No. 7, pp. 2161-2182. |
| Dellavalle A et al, “Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells”, Nature Cell Biology (2007), vol. 9, No. 3, pp. 255-267. |
| Docheva D et al., “Mesenchymal stem cells and their cell surface receptors.”, Current Rheumatology Reviews, vol. 4, (2008), vol. 4, No. 3, pp. 1-6. |
| Dominici M et al, “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.”, Cytotherapy (2006), vol. 8, No. 4, pp. 315-317. |
| Karlsson C. et al., “Human embryonic stem cell-derived mesenchymal progenitors—Potential in regenerative medicine.”, Stem Cell Research (2009), vol. 3, No. 1, pp. 39-50. |
| Lian Q. et al, “Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice.”, Circulation (2010), vol. 121, No. 9, pp. 1113-1123. |
| Mendes S. C et al, “Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny.”, Development (2005), vol. 132, No. 5, pp. 1127-1136. |
| Nowak, KJ, “Therapeutic Approaches for the Sarcomeric Protein Diseases.”, 2008. In: Laing N.G. (eds) The Sarcomere and Skeletal Muscle Disease. Advances in Experimental Medicine and Biology, vol. 642. Springer, New York, NY. 207-223. |
| Sampaolesi M. et al, “Cell therapy of a-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts.”, Science (2003), vol. 301, No. 5632, pp. 487-492. |
| Schubert CJ, “Muscular dystrophy meets the mesangioblast.”, Nature Medicine (2003), vol. 9, No. 8, p. 999. |
| Hart, et al., Identification, Cloning and Expression Analysis of the Pluripotency Promoting Nanog Genes in Mouse and Human, Developmental Dynamics, vol. 230, pp. 187-198 (2004). |
| Kim, Jeong Beom, et al. “Oct4-induced pluripotency in adult neural stem cells.” Cell 136.3 (2009): 411-419. |
| Maekawa, M., et al. “Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1.” Nature 474.7350 (2011): 225. |
| Yamamoto, T. “Development and differentiation of the Mesenchyme-derived cells” Journal of the Japan Society of the Reticuloendothelial System, vol. 29 Issue 4 pp. 277-284. 1989. With English Abstract. |
| Tonlorenzi, R., et al. “Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues.” Current protocols in stem cell biology 3.1 (2007): 2B-1. |
| Number | Date | Country | |
|---|---|---|---|
| 20200239840 A1 | Jul 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60989058 | Nov 2007 | US | |
| 60974980 | Sep 2007 | US | |
| 60919687 | Mar 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16137899 | Sep 2018 | US |
| Child | 16818958 | US | |
| Parent | 13793594 | Mar 2013 | US |
| Child | 16137899 | US | |
| Parent | 12053440 | Mar 2008 | US |
| Child | 13793594 | US |
